A longitudinal study of the metabolic syndrome and risk of colorectal cancer in postmenopausal women

European Journal of Cancer Prevention

Volumn 21, Issue 4, 2012, Pages 326-332

  Kabat, Geoffrey C ^a   Kim, Mimi Y ^a   Peters, Ulrike ^b   Stefanick, Marcia ^c   Hou, Lifang ^d   Wactawski Wende, Jean ^e   Messina, Catherine ^f   Shikany, James M ^g   Rohan, Thomas E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f STONY BROOK UNIVERSITY   (United States)

^g University of Alabama at Birmingham   (United States)

Author keywords

colorectal cancer; hyperinsulinemia; hypertension; insulin resistance; metabolic syndrome; obesity; postmenopausal women; time dependent covariates

Indexed keywords

GLUCOSE;

ADULT; AGED; ARTICLE; CANCER RISK; COLORECTAL CANCER; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HUMAN; LONGITUDINAL STUDY; METABOLIC SYNDROME X; POSTMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SYSTOLIC BLOOD PRESSURE;

AGED; CARCINOMA; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; METABOLIC SYNDROME X; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POSTMENOPAUSE; RISK FACTORS;

EID: 84861807742     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32834dbc81     Document Type: Article

References (54)

1. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR (2006). The metabolic syndrome and risk of incident colorectal cancer. Cancer 107: 28-36.
2. Alexander CM, Landsman PB, Teutsch SM, Haffner SM (2003). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52: 1210-1214.
3. Bergmeyer HU, Bernt E, Schmidt F, Stork H (1974). Determination of hexokinase and glucose-6-phosphate dehydrogenase. In: Bergmeyer HU, editor. Methods of enzymatic analysis. 2nd Engl. ed. New York: Academic Press. pp. 1196-1201.
4. Bjork J, Nilsson J, Hultcrantz R, Johansson C (1993). Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29. Scand J Gastroenterol 28:879-884.
5. Bowers K, Albanes D, Limburg P, Pietinen P, Taylor PR, Virtamo J, et al. (2006). A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 164:652-664.
6. Bruce WR, Corpet DE (1996). The colonic protein fermentation and insulin resistance hypotheses for colon cancer etiology: experimental tests using precursor lesions. Eur J Cancer Prev 5 (Suppl 2):41-47.
7. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K (2002). Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 11:385-391.
8. Dang CV, Semenza GL (1999). Oncogenic alterations of metabolism. Trends Biochem Sci 24:68-72.
9. Ford ES, Giles WH, Dietz WH (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356-359.
10. Gail MH (1981). Evaluating serial cancer marker studies in patients at risk of recurrent disease. Biometrics 37:67-78.
11. Giovannucci E (1995). Insulin and colon cancer. Cancer Causes Control 6: 164-179.
12. Giovannucci E (2007). Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86:s836-s842.
13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-2752.
14. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. (2008). Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 68:329-337.
15. Howard BV, Adams-Campbell L, Allen C, Black H, Passaro M, Rodabough RJ, et al. (2004). Insulin resistance and weight gain in postmenopausal women of diverse ethnic groups. Int J Obes Relat Metab Disord 28:1039-1047.
16. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M (2009). The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer 125:171-180.
17. Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H, et al. (2009). Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 18:240-247.
18. Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, et al. (2009). Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 45:1831-1838.
19. Jarvinen R, Knekt P, Hakulinen T, Rissanen H, Heliovaara M (2001). Dietary fat, cholesterol and colorectal cancer in a prospective study. Br J Cancer 85:357-361.
20. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005). Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194-202.
21. Kabat GC, Kim MY, Strickler HD, Shikany JM, Lane D, Lno J, et al. A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopousal women (submitted).
22. Koenuma M, Yamori T, Tsuruo T (1989). Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res 80:51-58.
23. Larsson SC, Wolk A (2007). Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr 86:556-565.
24. Limburg PJ, Stolzenberg-Solomon RZ, Vierkant RA, Roberts K, Sellers TA, Taylor PR, et al. (2006). Insulin, glucose, insulin resistance, and incident colorectal cancer in male smokers. Clin Gastroenterol Hepatol 4:1514-1521.
25. Marshall S, Bacote V, Traxinger RR (1991). Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266:4706-4712.
26. McKeown-Eyssen G (1994). Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 3:687-695.
27. Meigs JB (2003). Epidemiology of the insulin resistance syndrome. Curr Diab Rep 3:73-79.
28. Moghaddam AA, Woodward M, Huxley R (2007). Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70 000 events. Cancer Epidemiol Biomarkers Prev 16:2533-2547.
29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421.
30. Nilsen TI, Vatten LJ (2001). Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsu-linaemia hypothesis. Br J Cancer 84:417-422.
31. Ning Y, Wang L, Giovannucci EL (2010). A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev 11:19-30.
32. Oxentenko AS, Bardia A, Vierkant RA, Wang AH, Anderson KE, Campbell PT, et al. (2010). Body size and incident colorectal cancer: a prospective study of older women. Cancer Prev Res (Phila) 3:1608-1620.
33. Palmqvist R, Stattin P, Rinaldi S, Biessy C, Stenling R, Riboli E, et al. (2003). Plasma insulin, IGF-binding proteins-1 and-2 and risk of colorectal cancer: a prospective study in northern Sweden. Int J Cancer 107:89-93.
34. Park JY, Mitrou PN, Keogh RH, Luben RN, Wareham NJ, Khaw KT (2011). Self-reported and measured anthropometric data and risk of colorectal cancer in the EPIC-Norfolk study. Int J Obes (Lond) [Epub ahead of print].
35. Pelucchi C, Negri E, Talamini R, Levi F, Giacosa A, Crispo A, et al. (2010). Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer 46:1866-1872.
36. Peterson JI, Young DS (1968). Evaluation of the hexokinase-glucose-6- phosphate dehydrogenase method of determination of glucose in urine. Anal Biochem 23:301-316.
37. Sathyaprakash R, Henry RR (2002). Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep 2:416-422.
38. Schatzkin A, Hoover RN, Taylor PR, Ziegler RG, Carter CL, Albanes D, et al. (1988). Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Cancer Res 48:452-458.
39. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, et al. (1999). Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91:1147-1154.
40. Steiner P, Freidel J, Bremner W, Stein E (1981). Standardization of micro-methods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Clinics methodology. J Clin Chem 19:850.
41. Stocks T, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, Hallmans G, et al. (2008). Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond) 32:304-314.
42. Stocks T, Lukanova A, Bjorge T, Ulmer H, Manjer J, Almquist M, et al. (2010). Metabolic factors and the risk of colorectal cancer in 580000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer [Epub ahead of print].
43. Sturmer T, Buring JE, Lee IM, Gaziano JM, Glynn RJ (2006). Metabolic abnormalities and risk for colorectal cancer in the physicians' health study. Cancer Epidemiol Biomarkers Prev 15:2391-2397.
44. The Women's Health Initiative Study Group (1998). Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 19:61-109.
45. Tornberg SA, Holm LE, Carstensen JM, Eklund GA (1986). Risks of cancer of the colon and rectum in relation to serum cholesterol and beta-lipoprotein. N Engl J Med 315:1629-1633.
46. Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F (2001). Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 10:937-941.
47. Tsushima M, Nomura AM, Lee J, Stemmermann GN (2005). Prospective study of the association of serum triglyceride and glucose with colorectal cancer. Dig Dis Sci 50:499-505.
48. Van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, et al. (2011). Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 60:1094-1102.
49. Wang Y, Jacobs EJ, Patel AV, Rodriguez C, McCullough ML, Thun MJ, et al. (2008). A prospective study of waist circumference and body mass index in relation to colorectal cancer incidence. Cancer Causes Control 19: 783-792.
50. Warburg O (1956). On the origin of cancer cells. Science 123:309-314.
51. Warnick GR, Albers JJ (1978). A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 19:65-76.
52. Werner H, LeRoith D (1996). The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 68:183-223.
53. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J (1995). Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95: 1897-1905.
54. Yamada K, Araki S, Tamura M, Sakai I, Takahashi Y, Kashihara H, et al. (1998). Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol 27:794-798.